Optimal management of cancer anorexia–cachexia syndrome

Review

(3945) Views  (1507) Full article downloads

Authors: Josep M Argilés, Mireia Olivan, Sílvia Busquets, et al

Published Date January 2010 Volume 2010:2 Pages 27 - 38

DOI: http://dx.doi.org/10.2147/CMAR.S7101

Josep M Argilés, Mireia Olivan, Sílvia Busquets, Francisco Javier López-Soriano

Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain

Abstract: According to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of cancer patients before death and it is responsible for the deaths of 22% of cancer patients. Although bodyweight is the most important endpoint of any cachexia treatment, body composition, physical performance and quality of life should be monitored. From the results presented here, one can speculate that a single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful. The objectives of any therapeutic combination are two-fold: an anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective leading to the synthesis of macromolecules such as contractile proteins.

Keywords: wasting, cancer, anorexia, nutraceuticals, drugs